Národný Onkologický Program (NOP)

Objectives

Slovakia’s National Oncology Programme provides an equitable, evidence-based cancer-control framework spanning prevention, early detection, diagnosis, treatment, supportive and palliative care, survivorship, research, innovation, digitalisation and outcome assessment. Its overarching aims are to reduce cancer incidence and mortality and improve quality of life for people with cancer, while aligning national policy with Europe’s Beating Cancer Plan and the Horizon Europe Cancer Mission.[1][2]The programme is organised around prevention, screening, diagnosis and treatment, health data, research and education, with patient organisations expected to contribute across all action areas.[3]

• Reduce avoidable cancer risk through health literacy, healthy behaviours, environmental protection, tobacco and alcohol control, physical activity, healthy diet measures, and human papillomavirus vaccination for girls and boys.[4][5]
• Implement organised, population-based screening for breast, cervical and colorectal cancer, maintain high participation, and develop evidence-based proposals for additional screening for lung, prostate and stomach cancers.[6][7]
• Improve timely, affordable and high-quality diagnosis and treatment, including personalised medicine, innovative therapies, quality-assured diagnostics, comprehensive oncology centres and access to specialised care.[8][9]
• Expand survivorship, rehabilitation, psychosocial, supportive, palliative, terminal and hospice care for patients, families and carers, including support for return to work and disability rights.[10][11][12]
• Strengthen translational and clinical research, academic clinical trials, biobanking, research infrastructure and the use of registry, radiological, histological and genomic data.[13][14]
• Modernise the National Oncology Register and National Screening Register to improve the timeliness, completeness and analytical use of cancer data for prevention, screening and cancer-control decisions.[15][16]

Implementation

Implementation is structured through action plans for 2021–2025, combining Ministry of Health leadership with delivery by the National Oncology Institute, the National Centre of Health Information, public-health authorities, healthcare providers, health insurers, professional societies, universities, research institutions, patient organisations and European partners.[3][17][18]The National Oncology Institute has a central coordinating role in implementing action plans, supporting screening quality assurance, clinical research and programme reporting.[18]

• Coordinate screening through a National Oncology Screening Centre within the National Oncology Institute, with the Ministry of Health as guarantor and the Centre responsible for coordinating, monitoring and evaluating programmes and proposing updates.[19][20]
• Establish data exchange between healthcare providers, health insurers, the National Centre of Health Information, the National Oncology Institute, the Ministry of Health and authorised scientific or collaborating organisations to support screening oversight and evaluation.[21][22]
• Develop standard operating procedures for screening invitations, test quality, coding, reporting, data availability, quality control and programme evaluation, with annual quality-control reports and evaluation reports.[23]
• Deliver prevention through the updated European Code Against Cancer, continuous communication campaigns, support for the European Union cancer-prevention application, vaccination promotion and activities focused on behavioural risk factors.[24][25]
• Organise treatment across specialised oncology institutes, university hospitals, comprehensive oncology workplaces and more accessible local services, concentrating highly specialised procedures while providing chronic and palliative care closer to patients.[8]
• Develop major service capacity through a national comprehensive oncology centre, a chimeric antigen receptor T-cell treatment centre, a reference surgical oncology centre, a survivorship clinic, paediatric oncology services and expansion of the East Slovak Oncology Institute into a comprehensive centre.[26][27][28][29]
• Apply external quality assurance to diagnostic services, use specialist guidance and multidisciplinary cooperation in pathology, molecular biology and genetics, and support digital tools for symptom monitoring, patient-reported outcomes and care-quality assessment.[9]
• Build workforce capacity through specialist and continuing education for clinicians, clinical-trial coordinators, research nurses, epidemiologists, data managers and multidisciplinary support staff.[7][10][30]
• Advance research through the Biomedical Research and Development Roadmap, SLOVACRIN clinical-research infrastructure, clinical-trial networks, Ministry of Health grants, BIOHUB SK innovation support and national biobank development linked to European research infrastructure.[31][32][33][34]
• Monitor delivery through screening quality-control and evaluation reports, register-based analytical outputs, activity and vaccination measures, research and training outputs, and annual National Oncology Institute reports on action-plan implementation.[25][23][35][36][18]

Monitoring & Evaluation

Monitoring is centred on reducing cancer incidence and mortality, improving quality of life, and assessing research and innovation outcomes. The National Oncology Programme combines prevention, screening, treatment, survivorship, research and health-data actions, but the level of specification varies substantially across these areas.[2]

• Monitor primary prevention through annual budget measures, continuous communication campaigns, year-on-year numbers of activities, and human papillomavirus vaccination coverage, with baselines of 23% for girls and 1% for boys.[25]
• Coordinate and evaluate population screening through the National Oncology Screening Centre and National Screening Register, supported by data exchange between providers, insurers, the National Centre of Health Information, the National Oncology Institute and the Ministry of Health.[21]
• Apply continuous screening quality control and periodic evaluation against population, clinical and epidemiological parameters, including short- and long-term effectiveness and quality outcomes.[19][20]
• Publish screening quality-control reports annually, produce annual evaluation reports and cost analyses, and maintain public information on colorectal and mammography screening-facility networks.[23][37]
• Track screening delivery through active invitations to 90% of the target population for breast, cervical and colorectal screening during 2021–2025, while preparing proposals for lung, prostate and stomach screening.[6]

Data infrastructure is a major accountability mechanism. The National Oncology Register is to improve automated reporting, validation and analysis, addressing a reported position in which the latest data published in 2020 related to 2012 and passive reporting captured about 60% of patients.[15]Screening-register outputs are to be provided regularly or on request, and complete pseudonymised data from the screening and oncology registers are intended to support monitoring and evaluation.[36]

• Increase passive cancer case-data collection to more than 90%, eliminate reporting delays and automate screening-programme data collection.[38]
• Use digital tools, patient-reported symptoms and external diagnostic quality assurance to support care-quality assessment.[9]
• Assess radiotherapy through standard operating procedures focused on timeliness and efficiency, and assess surgical quality and availability through standard controls.[39][40]
• Track research implementation through clinical-trial activity, training sessions and participants, research-infrastructure roadmaps, grants, biobank development, innovation outputs and technology transfer.[41][30][35][42][43]
• Report annually on National Oncology Institute activities and implementation of the action plans.[18]

Named institutions provide operational responsibility, including the Ministry of Health of the Slovak Republic as screening guarantor, the National Oncology Institute as screening coordinator and evaluator, the National Centre of Health Information as a core data body, and the Ministry’s Scientific Council for research-grant evaluation.[22][33]However, many action areas do not specify common national indicators, reporting templates, targets, evaluation methods, sanctions or a consolidated accountability framework.[10][44][13]

Costing & Financing

Financing combines Ministry of Health allocations, National Oncology Institute and provider budgets, public health insurance, European Union programmes, Recovery and Resilience Plan resources, operational programmes and research grants. The source does not provide a consolidated National Oncology Programme budget, a quantified overall funding gap or consistent recurrent-cost assumptions.[2][29][13]

• Allocate EUR 600,000 in 2022–2025 to implement the updated European Code Against Cancer and support the European Union prevention application, alongside a further EUR 600,000 for behavioural-risk reduction and human papillomavirus vaccination.[25]
• Finance screening invitations and clinical procedures for colorectal, cervical and breast cancer through health insurance, while assigning screening-centre implementation and quality-control functions to National Oncology Institute resources.[23][37]
• Provide specified capital and service investments, including EUR 600,000 for a chimeric antigen receptor T-cell treatment centre, EUR 12 million for a reference surgical oncology centre, EUR 250,000 for a survivorship clinic and EUR 75 million for the East Slovak Oncology Institute comprehensive centre.[27][28][29]
• Support research infrastructure, clinical trials, biobanks, grants and innovation through national and European sources, including a stated combined Ministry of Health allocation of EUR 3,666,000 for listed research activities in 2021–2025.[31][35][42][45][43]
• Maintain the National Oncology Institute budget from EUR 493,500 in 2021 to EUR 613,500 in 2025; COVID-19 redirected or restricted funding for earlier activities rather than creating savings.[18]

Several activities are designated as having no financial impact, while other measures identify a funding source without an amount.[17][44][38]Preventive spending is contextualised by the estimate that prevention receives an average 3% of European Union health budgets, and EU4Health is described as a EUR 5.1 billion programme for 2021–2027.[3][2]Hospice and mobile-hospice provision are identified as insufficiently reimbursed, and academic clinical research is described as lacking adequate systemic financial support, but neither gap is quantified.[11][41]